Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin filed a joint Schedule 13G with the SEC on November 17, 2026, disclosing beneficial ownership of 1,800,000 shares of GeneDx Holdings Corp. Class A common stock as of November 10, 2026.

Key Highlights

  • Three reporting persons: Deep Track Capital, LP (Delaware), Deep Track Biotechnology Master Fund, Ltd. (Cayman Islands), and David Kroin (United States) filed jointly.
  • Beneficial ownership: Each reporting person is listed as beneficially owning 1,800,000 shares of Class A common stock, par value $0.0001 per share.
  • Percent of class: The 1,800,000 shares represent 6.01% of the class, based on 29,972,493 shares outstanding as of November 2, 2026.
  • Voting and dispositive power: All 1,800,000 shares are held with shared voting power and shared dispositive power; sole voting and sole dispositive power are each reported as 0.
  • Triggering event date: The date of the event requiring the filing is listed as November 10, 2026.
  • Control person relationship: According to the filing, Deep Track Capital, LP is the relevant entity for which David Kroin may be considered a control person.

Deep Track Capital's Schedule 13G Filing on GeneDx Holdings Class A Shares

According to the filing, Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin submitted a joint Schedule 13G disclosing a combined beneficial ownership position in GeneDx Holdings Corp. (NASDAQ:WGS). The issuer is identified in the filing as GeneDx Holdings Corp., with principal executive offices at 333 Ludlow Street, North Tower, 6th Floor, Stamford, Connecticut 06902. The securities covered are Class A common stock, par value $0.0001 per share, with CUSIP number 81663L200.

The filing reports that all three parties beneficially own 1,800,000 shares, representing 6.01% of the class. This percentage was calculated using 29,972,493 shares outstanding as of November 2, 2026, as reported by GeneDx Holdings Corp. in its 10-Q filed with the SEC on November 9, 2026, according to the filing. Each reporting person holds shared voting power over all 1,800,000 shares and shared dispositive power over the same amount, with zero sole voting or dispositive power reported for any party.

The filing states that the securities "were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11." Deep Track Capital, LP is listed with a business address of 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830, and David Kroin signed the filing in his capacity as Managing Member of the General Partner of the Investment Adviser for Deep Track Capital, LP, as Director of Deep Track Biotechnology Master Fund, Ltd., and individually.

What Was Disclosed

A joint Schedule 13G filed November 17, 2026, discloses that Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin each beneficially own 1,800,000 shares, or 6.01%, of GeneDx Holdings Corp. Class A common stock, with all voting and dispositive power shared among the reporting persons.